Loading company…
Prexa develops oral small-molecule monoamine reuptake inhibitors for neurological and psychiatric conditions.
Founded in 2006, Prexa is developing oral small-molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. The company aims to develop treatments for ADHD, depression, and Parkinson’s disease.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in